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Introduction
During the course of this conference it has become
clear that the application ofin vitro, as well as in vivo,
models fortoxicity might be able to help us a great deal
in our efforts to conduct more accurate species-to-spe-
cies extrapolations of risk. However, the question
remains: How do we monitor populations to determine
if a particular biochemical pathway might have been
perturbed or to determine if a particular population or
individual might be sensitive or resistant to the actions
of a given chemical?
In our attempts to address this question, the term
"surrogate markers" has developed. These are markers
which should be reflective of what's happening in the
target cell or target organ. The most commonly used
surrogate markers have been those that have measured
concentrations of a chemical or its metabolites in body
fluids or tissues, including urine, blood, and to a lesser
extent, hair, milk, placenta, amniotic fluid, and fat. For
the purpose of this discussion, it might be useful to
classify them together as surrogate markers.
The basis for using markers in risk assessment and
human monitoring reflects our growing knowledge of
the mechanisms responsible for chemically induced dis-
ease. Figure 1 illustrates a general scheme for the
sequence of biochemical events that occur between
exposure and outcome. Itisimportanttonote thatwith-
out knowledge of mechanism, it is not possible to dif-
ferentiate between amarkerofan exposure and amark-
er of an effect. Furthermore, the development of sus-
ceptibility markers also requires knowledge of mecha-
nism. The appropriate use of susceptibility markers
might offer an opportunity toidentify individuals at risk
and explainthe huge interindividual variationin respon-
siveness to many chemicals. The use ofthe terms mark-
ers of exposure, markers ofeffect, and markers of sus-
ceptibility reflects the definitions used by a recent
National Academy of Sciences panel (1).
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The use of surrogate markers requires validation in
humans. The validation is generally considered to con-
sist oftwo processes. One is sensitivity and one is spec-
ificity. "Sensitivity" might be defined as the ability to
adequately detect the nature of the chemical exposure
of a given individual. When sensitivity is high, the
occurrence offalse negatives is low. Specificity reflects
our ability to correctly classify individuals who are not
exposed or who do not exhibit an adverse health effect.
When specificity is high, false positives are low.
One approach that might be used in the development
of surrogate markers requires the availability of ade-
quate animal or cellular models for the toxic effects
characteristic ofthe chemicalbeingstudied. In ouropin-
ion, the validation of surrogate markers is not possible
without such in vivo or in vitro models. Validation
requires characterization ofthe markers in that animal
model throughout the time course of the disease pro-
cess. It is then necessary to determine which of those
markers can be determined noninvasively. And finally,
this information must be applied to the human condition
followingeitherenvironmental, occupational, ormedical
exposures.
For the purpose of discussion, there are several dif-
ferent kinds ofsurrogate markers that have been used.
These are listed in Table 1 and will be briefly summa-
rized (1-7).
Chemical or Its Metabolites in Biological
Media
The advantages ofquantitating a chemical and/or its
metabolites in body fluids is that it can provide a very
specific marker for identifying exposure to well-char-
acterized chemicals. Moreover, with recent advances in
analytical chemistry, the current levels of detection
offer increased sensitivity. However, there are some
disadvantages to this procedure. Chemical detection
will not reflect past exposure to rapidly metabolized
chemicals. More importantly, levels ofchemical in body
fluids is not necessarily reflective of the interaction of
thechemicalwithcriticalmacromolecules intargetcells.LUCIER AND THOMPSON
Exposure -aPharmacokinetics Biologically Effective Dose
(P.450 isozymes ' (DNA-adducts; receptor occupancy)
conjugation Rxns) L1
Toxic Response Critical changes Markers of exposure
(tumor incidence) in gene expression not associated with
(oncogenes; growth mechanism
factor responses)
FIGURE 1. Mechanistic basis for the use of biomarkers in risk as-
sessment and epidemiology.
Table 1. Surrogate markers.
Chemical or its metabolites in biological media







Mutagenic Activity in Fluids
Testing for mutagenic substances in urine obtained
from chemically exposed persons hasbeen awidelyused
monitoring technique. The use of this marker may be
helpful in detecting exposures to complex mixtures
when the identification of the toxicant is unknown. In
its present state, these tests thus far have been quali-
tative rather than quantitative and are oflimited value
beyond possibly indicating that an exposure has oc-
curred. This test is obviously not specific and usually
not very sensitive.
Cytogenetics
Analyses of sister chromatid exchange (SCE) fre-
quencies and chromosomal aberrations inperipheral hu-
man lymphocytes have been conducted in chemically
exposed groups. The mechanism responsible for induc-
ing SCEs is not understood; however, many classes of
carcinogens and mutagens are known to produce in-
creased SCE frequency. Thesignificanceofthisincrease
in relation to disease outcome is unclear. Unlike SCE,
which 'is an S-phase-specific phenomenon, chromosomal
aberrations can occur at any point of the cell cycle.
Moreover, there is increasing evidence which suggests
that chromosomal aberrations might be linked to the
carcinogenic process for some chemicals. Like tests for
detecting mutagens in body fluids, cytogenetic analyses
might be useful for detecting exposure to complex mix-
tures but are generally not specific and in many cases
not very sensitive.
Gene Mutation
Unlike the previously described assays, gene muta-
tion is the result of direct damage to DNA. Currently,
somatic mutation of the HPGRT gene locus in human
lymphocytes is being evaluated as a monitoring tool, as
is the loss of an allele at the glycophorin A locus in
erythrocytes. These assays have been used to detect
exposure to cancer chemotherapy agents but have not
successfully been applied to environmental exposures.
They are in the early stages of development, but do
offerthe advantage fordetectingcurrent aswellas past
exposures. It remains to be seen what the relationship
will be between elevated mutant frequencies at these
sites and primary or secondary (in the case of chemo-
therapy patients) cancer.
An exciting approach for monitoring gene mutation
that offers the opportunity to be both sensitive and
specific is being developed. It involves enzymatic am-
plification ofmutant gene sequences followed by analy-
sis on gradient denaturing gels (3). This technique
avoids the clonal expansion of mutant cells (as is nec-
essary for HPGRT) by selective pressure and therefore
might allow one to identify a broader spectrum ofmu-
tations.
Nucleic Acid and Protein Adducts
Several methods to detect DNA-chemical adducts in
exposed persons are currently available. These include
synchronousfluorescence spectrophotometry, detection
by monoclonal or polyclonal antibodies, and 32p post-
labeling. The potential advantages ofdirectly measur-
ingDNAadductsisthatitcanbeusedasameasurement
of the biologically effective dose and thereby take into
accounttheinterindividual variationinpharmacokinetic
parameters. Monoclonal antibodies offer the advantage
of being specific. The 32p postlabeling method is ex-
traordinarily sensitive and has the potential to detect 1
adduct in 1010 normal nucleotides. Unlike detection by
monoclonal antibodies, which requires considerable
knowledge of the DNA-chemical adduct and can only
be used when appropriate antibodies are available, 32P
postlabeling picks up most bulky DNA adducts. How-
ever, there are some disadvantages with this assay.
With currentmethodologicalprocedures, itis onlysemi-
quantitative. Inpopulationmonitoringstudies, itshould
be noted that the level of DNA chemical adduct meas-
ured in peripheral lymphocytes may or may not be rep-
resentative of levels found in target tissues.
There is increasing belief that hemoglobin adducts
may be a good dosimeter of exposure for human pop-
ulations. Steve Tannenbaum's work with the 4-amino
biphenyl hemoglobin adducts (8) demonstrates that it
is a quite sensitive marker to detect exposure to ciga-
rette smoke, and perhaps otheramines aswell. Because
ofthe longevity (120 days) oferythrocytes, some infor-
mation can be obtained about past exposure. There is
evidence that hemoglobin adducts may be good indi-
cators ofDNA damage; dose-response relationships are
similar to those for DNA adducts for some chemicals.
One ofthe disadvantages ofthis assayisthatitrequires
expensive equipment, and, as with DNA adducts, ad-
duct levels in hemoglobin may not accurately reflect
actual exposure oftarget tissues.
188DISCUSSION: LYMPHOCYTES AS SURROGATE MARKERS
DNA Repair
Methods to monitor DNA damage and/or repair in
humans following chemical exposure include alkaline
elution, unscheduled DNA synthesis, and nucleoid sedi-
mentation. Though widely used in animal studies, these
assays still require validation in humans. As markers
ofexposure, these assays generally lackboth specificity
and sensitivity. The potential strength of these assays
may be there use as markers of susceptibility rather
than markers of exposure. Repair deficiencies in indi-
viduals may be identified by exposing lymphocytes in
vitro with different classes ofchemical carcinogens. Nu-
cleoid sedimentation assays may offer the advantage of
detecting both repair deficiencies as well as damage.
Receptor Interactions
Inasmuch as many carcinogens appear to act through
nongenotoxic mechanisms, markers need to be devel-
oped that reflect the complex nature ofthe interactions
between receptor systems, signal transduction path-
ways (e.g., EGF, steroid receptors, protein kinases,
TPA receptors), and regulation ofcellular proliferation.
Ifwe could adequately measure receptor occupancy, for
example, for estrogens or TCDD, perhaps we might
have a good monitor of a biologically effective dose in
humans following exposure either to environmental es-
trogens or to the toxic halogenated aromatics. The dis-
advantage of these assays is that tumor promotion in-
volves several poorly understood stages, thus making
it difficult to evaluate the relationship between altered
receptor interactions and adverse effects.
Tumor Markers
Tumor markers have been used to a limited extent.
Alpha-fetoprotein has probably been the most widely
usedmarkerandhasdetectedearlyformsoflivercancer
in some populations. The disadvantages oftumormark-
ers is that they are detecting relatively late stages in
the carcinogenic process. For the most part, they are
neither specific nor sensitive.
Conclusion
In conclusion, unless we understand mechanism of
action, the use ofsurrogate markers is limited to mark-
ers ofexposure. Without animal models to verify dose-
response relationships, they are also limited. However,
the rapid advances in molecularbiology may offertract-
able approaches to develop teststhat areboth sensitive,
specific, and more predictive ofoutcome. It, therefore,
would seem prudent to collect samples from exposed
populations for the purpose ofconducting validated as-
says now and storing samples for assays under devel-
opment that promise to have increased sensitivity and
specificity.
Discussion
DR. Roy ALBERT, UNIVERSITY OF CINCINNATI
MEDICAL CENTER: I'm not sure that you answered the
question. When can lymphocytes be used as surrogate
markers?
DR. LUCIER: Let's provide a basis for discussion. I
think they can be used in a situation in which you have
information about the mechanism and you have an ade-
quate animal or in vitro model in which to verify your
observations, especially dose-response relationships. I
think everyone would agree that these kinds of obser-
vations can be very useful in detecting exposures, and
theyhave beenusedtodetectexposures. Butwhatdoes
it mean when you have agiven concentration ofa chem-
ical in blood or an increase in sister chromatid ex-
changes? I'm not sure I understand what that means
toxicologically. Itmay mean thatthese individuals have
been exposed to a mutagenic agent. I don't know the
general feeling of this audience. Nevertheless, bio-
markers are goingtobeusedincreasinglyaswe develop
molecular epidemiological approaches. The basis of
these approaches is the availability of valid surrogate
markers.
Unless we struggle with these markers (what they
mean, what they're telling us), we're going to get our-
selves into a situation where we have apile ofdata that
says, "Yes, this population may have been exposed, it
may have been exposed more than the other one." But
it's not going to tell us too much about outcome, unless
we understand the toxicological basis of those obser-
vations. I think in some cases surrogate markers may
be reflective of what's happening in the organ system
of interest; in other cases they won't be. It seems to
me that some sort ofanimal or in vitro model is needed
to determine this.
UNKNOWN SPEAKER: One of the tougnest problems
is the issue of validation, for example, cytogenetic ef-
fects where you do have some reproducibility in meth-
odology, at least these assays have been around for
quite some time. How do you see goingabout validating
the use of these as any index? Because you can't just
look at those that have been exposed to hazardous sub-
stances. You've also got to accommodate the back-
ground frequency and exposures to nonhazardous sub-
stances that may have caused the same effect. I see
validation as a real perplexing problem.
DR. LUCIER: Thebiggestproblemwiththe validation
ofmarkers, I think, is tying them to toxic effects. The
approach is to take apopulation, and saythispopulation
has been exposed to cigarette smoke. They have an
overall increase in SCEs. But the increase in SCEs is
very small, sometimes not even statistically significant.
Yet you have a population that is going to go on and
get a fairly high incidence of cancer. Whereas, in an-
other case, another exposure might cause a greater in-
crease in SCE frequency and the outcome might not be
as severe. So I think the question ofvalidation is a very
difficult one because the quantitative relationship be-
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tweenthe magnitude ofthechange and effectisfarfrom
clear.
I think we currently have some reliable markers of
exposure and they may be good dosimeters in some
cases. However, people who start talking about mark-
ers of effect, at this point, are whistling in the wind.
DR. RAYMOND TENNANT, NIEHS: I guess the point
that you're making and that I tried to make before is
in the interspecies extrapolation ofdata. These are the
same types of parameters that one can measure in the
short-term assays that I was discussing in my presen-
tation. And I think we can put the best face on this in
saying that although we don't understand how much
mutagenic activity in the urine becomes significant to
the person who is ever going to get a tumor, I think it
is still significant that we measure this. And I think it
is important to identify what is the mutagenic activity
ofcertain compounds in humantissue orin humanurine
of exposed individuals. Because even though we don't
understand the whole pathway right now, it's certainly
worth the effort because the significance ofthese mea-
surements might be more clear in the future.
DR. JULIAN PETO, ROYAL CANCER HOSPITAL, ENG-
LAND: Is there extractable and clonable DNA in frozen
blood samples that you might be able to look at to es-
timate frequency of mutation or DNA adducts that
might have been caused by chemical exposures?
DR. LUCIER: YOu certainly canlookat DNA adducts.
They're very stable. I don't know if frequency of mu-
tations could be reliably estimated in these samples us-
ing current methodology.
DR. PETO: Could you clone the extractable DNA?
DR. LUCIER: I don't know ifyou could do that or not.
Could anyone comment on that?
DR. PETO: You'd want topullthe same segment from
two bits. You'd want to go to DNA twice in the same
sample, pullthe same sequence twice, andthencompare
themtoseewhatsortofmutationswerepresent. Maybe
mutation is so difficult to estimate (vanishing) that it's
not technicaliy feasible. But it's the sort of thing that
could be presumably done.
DR. LUCIER: Themutationfrequency inexposedpop-
ulations is probably very low, and some ofthe mutation
assays are complicated by a varying baseline, such as
the HPRT locus, so the low frequency coupled with the
varying baseline and the fact that these samples might
have been stored alongtime suggests thatit's probably
not too practical atthis time. However, some ofthe new
techniques under development, such as amplification of
mutant genes, may lead to approaches to detect low
frequency mutations caused by chemicals.
DR. ALBERT: One of the problems in cancer epide-
miology in industry is trying to reconstruct a past ex-
posure, which can vary because ofchanges in processes
orchanges injobs, and I wonder to what extent can the
lymphocytes be used to reconstruct the magnitude of
cumulative past exposure?
DR. LUcIER: Well, many lymphocytes live a long
time, up to 3 years. So, it is possible to gather some
cumulative information bylooking atlymphocyte mark-
ers such as DNA adducts. However, quantitation of
blood concentrations of a chemical or metabolite that's
rapidly metabolized would not be useful in reconstruct-
ingpastexposures. ForlookingatsomethinglikeTCDD
or the dibenzofurans or the PCBs, which are extraor-
dinarily persistent, you can look several years later and
get an idea ofpast cumulative exposure. So I think the
point would be that you have to evaluate each marker,
whether it be a DNA adduct or whether it be a hemo-
globin adduct or DNA repair or receptor interaction
coupled with knowledge ofthe persistence ofthe chem-
ical and then make a determination as to whether or
notitwouldbeuseful. So I don'tthinkthereisaunifying
rule that would be useful. I think each chemical would
have to be treated and each marker as a separate case.
UNKNOWN SPEAKER: What's the replicatingcapacity
oflymphocytes when they're hit with a mitogen?
DR. LUCIER: It's very rapid, and that's how one ana-
lyzes for SCEs. When you hit lymphocytes with mito-
gens you induce a number of changes such as in the P-
450 systems, which can metabolically activate any num-
berofchemicals. Soifyouincubatebenzo[a]pyrenewith
lymphocytes in the presence of a mitogen, you can get
a lot of DNA adducts because the metabolic activation
capacity is there in those lymphocytes, but that's not
an in vivo monitoring situation. That's fine for in vitro
perturbations of your system to evaluate markers of
susceptibility, but this information does not necessarily
provide a marker of effect.
DR. ALBERT: Have adducts in the brain been looked
at? The brain contains neurons, which have essentially
zero turnover, suggesting that they might be useful,
although not as a noninvasive method. But in terms of
autopsy or surgical material, the brain might provide a
population measure of the buildup of adducts. What
about adducts in the brain? Has that been looked at?
DR. LUCIER: In relation to animal models there's
quite a bit of data on that. Adducts are found in the
brain, usuallyfoundatalowerconcentration, thanmany
other tissues, although I don't know the structure-ac-
tivity relationships. I don't know if adducts could be
found in autopsy patients. The only way of looking at
thatwould bethrough apostlabeling procedure ormon-
oclonal antibody methods. You obviouslywouldn't have
treated that individual with a radioactive chemical to
detect the DNA adduct. The method that Dr. Reddy
talked about earlier (postlabeling) can possibly detect
one adduct in a billion normal nucleotides. Perhaps by
that method you might be able to detect some in those
victims.
DR. ALBERT: You could have an occupational expo-
sure that goes on for 30 years, the individual dies. You
knowwhathewasexposedto. Couldyouusemonoclonal
antibodies?
DR. LUCIER: Yes. You could use a monoclonal anti-
body to look at the adduct. But you have to remember
there's some cross-reactivity with some ofthese, soyou
may get erroneous information unless you're careful. I
would expect you could pick up adducts in the brain by
the postlabeling procedure. They're picking them up in
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virtually every tissue in control animals. So there's no
reason why a so-called control human being wouldn't
have them as well. But how you would relate that back
to the exposure that had occurred I don't know, unless
you had adequate controls to determine ifthose adduct
spots were in fact different than the controls.
DR. ALBERT: I want to thank all the speakers and
the participants forthe discussion and close the session.
Dave, do you want to give a benediction?
DR. HOEL, NIEHS: Iwanttothankeveryone. Ithink
this has been a successful conference. I certainly en-
joyed manyofthetalks. I'mgladtoseethatafewpeople
have lasted to the bitter end. And, I guess we will press
hard to get manuscripts and get the publication out. I
think the thing to do is to look for it in the EHP.
Thank you very much.
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